CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases. Under the terms of the agreement, Alentis will receive a… Read More
Eli Lilly and Gate Bioscience have expanded their collaboration to discover, develop, and commercialise molecular gate therapeutics. The expanded collaboration adds one target, with the opportunity to add a second target, to the companies’ existing work. The programmes leverage Gate’s Molecular Gate drug discovery engine… Read More
Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More
SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide. SciBrunch will receive… Read More
Scarlet Therapeutics has entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) to advance the development of smart red blood cells (SRBCs). Scarlet will lead a multidisciplinary consortium to develop SRBCs in a programme worth up to $14 million. The agreement builds… Read More
A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases. The collaboration includes development of long-acting injectable formulations with different administration-frequency… Read More
Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. Under the terms of the agreement, Orbis Medicines is eligible to receive up to $1.4 billion in upfront and potential development and commercial milestone… Read More
Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases. Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for… Read More
Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets. Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments,… Read More
Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours. The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY… Read More
Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More
Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will use Evotec’s data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across… Read More
Pharmaceutical company GSK has announced a strategic collaboration with the biotech Relation to improve the understanding of disease biology and support the discovery of new therapeutic targets. Specifically, the partnership will focus on generating large-scale human cellular perturbation data and deploying them into models, such as Relation’s… Read More
Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration. The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More
Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies. Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology… Read More
Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion. The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads… Read More
